CSPC Innovation Pharmaceutical Hits Day Low Amid Price Pressure at CNY 30.21

CSPC Innovation Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.23% and reaching an intraday low of CNY 30.21. This performance contrasts with the China Shanghai Composite, which saw a slight decrease of 0.1% on the same day. Over the past month, CSPC has faced significant challenges, with a decline of 11.25%, while the broader market remained relatively stable, down just 0.12%. The company's financial metrics indicate ongoing difficulties, as it has reported negative results for six consecutive quarters. Notably, net profit for the first half of the year plummeted by 96.01%, and operating cash flow reached a low of CNY -449.2 million. Additionally, the return on capital employed (ROCE) stands at a concerning -2.92%. Despite a strong performance over the past five and ten years, CSPC's recent trajectory has raised concerns, particularly as it has underperformed the market significantly over the last year, generating negative returns of 16.89% compared to the China Shanghai Composite's positive 22.30%. The company's current market capitalization is CNY 47,166 million, placing it within the large-cap category in the FMCG industry.